)
)
Edge16 Oct 2026
Winner, Winner: The Chicken McNugget Story
How a 1940s breeding contest, a Cornell food scientist, and a hedge by Ray Dalio helped McDonald's turn the Chicken McNugget into a fast-food icon.
InMode
InMode (INMD) investor relations material
InMode Q3 2026 earnings summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Q3 2026 earnings summary11 Nov, 2026
Executive summary
Q3 2026 revenue was $92.1M, broadly in line with Q3 2025; FY 2026 guidance was reaffirmed.
U.S. and international capital equipment revenue was relatively stable QoQ, with stabilization expected through year-end.
The global RF-based aesthetics and wellness platform spans 104 countries, 12 product families and 33,400 installed units; U.S. installations totaled 14,000, supported by 298 direct sales reps.
Financial highlights
Q3 GAAP revenue was $92.1M vs. $93.2M; nine-month revenue was $269.7M vs. $266.6M.
Q3 GAAP net income was $18.9M and diluted EPS was $0.32; non-GAAP net income was $21.9M and diluted EPS was $0.37.
Nine-month GAAP net income was $47.5M vs. $66.8M; non-GAAP net income was $58.6M vs. $76.1M.
Outlook and guidance
FY 2026 guidance reaffirmed: revenue of $365M–$375M, non-GAAP gross margin of 74%–76%, non-GAAP operating income of $68M–$73M and non-GAAP diluted EPS of $1.29–$1.34.
Guidance reflects current estimates; forward-looking outcomes are subject to risks and uncertainties.
Pipeline aims to expand medical offerings and adapt proprietary RF technologies for plastic surgery, OB/GYN, ENT and ophthalmology.
Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.Research faster. Power your platform.
Latest events from InMode
- Q2 2026 saw stable revenue, margin pressure, and strong cash flow with robust Asia growth.INMD
Q2 2026 - Product innovation, high margins, and disciplined capital allocation drive growth amid macro headwinds.INMDJefferies Global Healthcare Conference
- Strong innovation and global expansion position the firm for recovery despite current headwinds.INMDCanaccord Genuity 44th Annual Growth Conference & Private Company Showcase 2024
- Flat revenue outlook, margin pressure, and new products set the stage for future growth.INMDJefferies Global Healthcare Conference 2026
- Q1 2026 revenue reached $82M with 75% gross margin and ongoing share repurchases.INMDQ1 2026
- Growth from new products offsets margin pressure; global expansion and R&D drive future potential.INMD25th Annual Needham Virtual Healthcare Conference
- Manufacturing and logistics face disruption, but strategic buybacks and global expansion continue.INMDOppenheimer 36th Annual Healthcare MedTech & Services Conference
- Revenue was $130.2M, margins declined, but new platforms gained traction amid headwinds.INMDQ3 2024
- Revenue and margins fell as U.S. demand softened, but international growth and capital returns continued.INMDQ1 2025
Next InMode earnings date
Q4 202610 Feb, 2027
InMode
Next InMode earnings date
Q4 202610 Feb, 2027
AI chat
Ask anything. Verify everything.
Ask across every event and document from public companies. Each answer links back to the exact line in the transcript, slide or filing it came from.Learn moreFind what matters
AI across all first-party IR material. Live calls, transcripts, slides, filings.)
Trust every finding
50m+ first-party documents. Every output traceable to its source.Find what matters
AI across all first-party IR material. Live calls, transcripts, slides, filings.Trust every finding
50m+ first-party documents. Every output traceable to its source.Automations
Zero in on what matters
Define the prompt once. It runs the moment a company publishes or on a schedule you set. Outputs map to the exact signals you choose.Learn more)
Event-triggered research
Runs when a company publishes new material. Trigger on the first published document for the earliest possible run, or wait for a specific one.)
Scheduled research
Runs on a recurring cadence you set. Daily, weekly, monthly, or quarterly, for aggregate reads across a period rather than a single event.Event-triggered research
Runs when a company publishes new material. Trigger on the first published document for the earliest possible run, or wait for a specific one.Scheduled research
Runs on a recurring cadence you set. Daily, weekly, monthly, or quarterly, for aggregate reads across a period rather than a single event.Live audio & transcripts
Be first
Join any earnings call live in one click, with no manual registration. Follow the transcript as it happens and jump straight to the moments that matter.Learn more)
Live earnings calls
Join any call in one click. The audio keeps playing while you work elsewhere in Quartr.)
Live transcripts
Speaker-by-speaker, in real time. Searchable across every live and historical call.Live earnings calls
Join any call in one click. The audio keeps playing while you work elsewhere in Quartr.Live transcripts
Speaker-by-speaker, in real time. Searchable across every live and historical call.Quartr MCP connects your AI environment to 17K+ public companies
Pull live transcripts, filings, and slides into Claude or Codex via MCP. Combine Quartr's global IR data with any other dataset. Run agentic research and monitoring.
Included with Quartr Pro at no extra cost.Learn more
Quartr's AI stands out because it only pulls clean, first-party data from public companies. In investing, that's everything.
Jamie Ross
Investment Manager, GAM Investments
GAM
GAM
Research that used to take hours now takes seconds with Quartr Pro. Tracking shifts in tone or extracting tables, it's as simple as typing a query.
Tom O'Hara
Investment Director
Ciena
Ciena
Before Quartr we spent hours manually compiling insights through the peer earnings cycle. Now, these tasks are done faster, with greater precision.
Gregg Lampf
VP of Investor Relations
Protean
Protean
Being able to ask specific questions across years of transcripts and reports and instantly get verified answers is a game-changer.
Pontus Dackmo
CEO & Investment Manager
)
)
Frequently asked questions
A leading provider of minimally invasive treatments
InMode is a medical technology company that specializes in developing innovative solutions for minimally invasive cosmetic and medical procedures. The company was founded in 2008 and has since become a leading provider of minimally invasive aesthetic and medical treatments. Some of InMode’s competitors include Cutera, LivaNova, and TransMedics.
The business model
InMode's business model is based on developing and marketing cutting-edge medical technology solutions to meet the specific needs of physicians and patients around the world. The company's products and services include minimally invasive treatments for body contouring, skin rejuvenation, women's health, and more.
How InMode makes money
InMode generates revenue primarily through the sale of its medical technology products, as well as through ongoing customer support and service contracts. The company's revenue is also generated through its partnerships with other healthcare companies and organizations, as well as through collaborations with academic research institutions and other organizations.
Revolutionizing the field of medical aesthetics
InMode has developed and patented a range of advanced technologies that have revolutionized the field of medical aesthetics. One such technology is its BodyTite system, which uses radiofrequency energy to deliver heat to targeted areas of the body, tightening the skin and reducing fat without the need for surgery. The company has also developed minimally invasive treatments for vaginal rejuvenation, hair removal, and tattoo removal, among others.